Breaking News

BioClinica Launches StudyView

June 26, 2013

Reporting hub designed to increase clinical trials operational visibility

BioClinica, Inc. has introduced StudyView, a clinical trials portal and reporting hub designed to increase clinical trials operational visibility. StudyView provides one tool to access multiple eClinical applications, as well as analyze and report data across studies. StudyView is fully integrated with BioClinica's product suite and is 21 CFR Part 11 compliant. 

StudyView leverages Microsoft business intelligence technologies such as Power View to create interactive dashboards and SQL Server Reporting Services (SSRS), enabling users to build a range of summary and granular reports and surface them in SharePoint 2013 to support further analysis and action. According to the company, StudyView is a clean, modern portal that eliminates the need for multiple logins and data flows seamlessly between applications.

"Achieving real-time operational visibility of clinical studies data can be difficult, especially when multiple systems are involved," said Peter Benton, BioClinica's president of e-Clinical Solutions. "Now you can get the answers to critical clinical study operations questions in one place. This is the kind of cross-system operational metrics visibility that is a necessary cornerstone of any risk-based monitoring plan."

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research